Aa
altrombopeg?
Hi!
I have extremely low blood platelets due to my cirrhosis. Has anyone heard anything about the drug altrombopeg, which is used to boost up platelets?
Thx
I have extremely low blood platelets due to my cirrhosis. Has anyone heard anything about the drug altrombopeg, which is used to boost up platelets?
Thx
It's FDA approved for use in patients who have ITP (IdiophaticTrombocytopenia Purpura) only. The doctors who prescribe it have to register the patient in a program called "Promacta Cares" so that the FDA can keep track of the patients.
There is a recent study that showed that many Hep C patient have ITP. Perhaps you can use it to get your doctor to prescribe it for you.
Co
HCV-Infected Individuals at Increased Risk for Immune Thrombocytopenia Purpura and Autoimmune Hemolytic Anemia.
Eurona Earl Tilley
February 26, 2009 — The incidence of 2 severe autoimmune cytopenias — immune thrombocytopenia purpura (ITP) and autoimmune hemolytic anemia (AIHA) — has been shown to be elevated among individuals infected with hepatitis C virus (HCV). Research published in the February 23 issue of the Archives of Internal Medicine reveals that HCV-infected patients in the Veterans Affairs (VA) health system were at increased risk of developing ITP. However, those who underwent treatment were also at increased risk for AIHA.
"Prior studies suggesting that HCV might be an etiologic risk factor for the development of autoimmune cytopenias have been based on small series of patients from single institutions," write Elizabeth W. Chiao, MD, MPH, from the Department of Medicine, Baylor College of Medicine, Houston, and the Houston Center for Quality of Care and Utilization Studies, Health Service Research and Development Service, Michael E. DeBakey Veterans Affairs Medical Center, Texas, and colleagues. "To our knowledge, no large study has been conducted. Given that US military veterans have a high prevalence of HCV infection (5%), this population provides a unique opportunity to observe HCV-related phenomena."
To determine the effect of HCV infection on the incidence rates of ITP and AIHA, researchers analyzed the inpatient and outpatient records as well as pharmacy data from HCV-infected (n = 120,691) and matched uninfected (n = 454,905) veterans. The diagnosis of ITP and AIHA was identified via hospitalization codes. Those with a prior diagnosis of lymphoproliferative disease, HIV, or cirrhosis were excluded from the analysis.
"In this large national cohort study including over half a million US veterans, we observed HCV-infected persons to be at increased risk of ITP and AIHA," explain the authors. A Cox proportional hazards regression model revealed that the hazard ratios (HRs) for ITP and AIHA were 1.8 (95% confidence interval [CI], 1.4 – 2.3) and 2.8 (95% CI, 1.8 – 4.2), respectively.
"Because both ITP and AIHA have been previously associated with interferon alfa use, we were also interested in assessing pharmacy data to account for the effects of HCV treatment," write Dr. Chiao and colleagues. While the incidence of ITP was elevated among both treated and untreated HCV-infected individuals, the incidence of AIHA was only elevated among those who had received treatment (HR, 11.6; 95% CI, 7.0 – 19.3).
These findings were further illustrated by examining the Kaplan-Meier curves of the cumulative incidence of each of the outcomes. The cumulative incidence of ITP was significantly greater among HCV-infected individuals vs matched control individuals (P < .001) and remained significant following censorship at the time of treatment (log rank test; P = .002). However, the cumulative incidence of AIHA was significantly greater among HCV-infected individuals vs matched control individuals (P < .001), but this difference was no longer significant following censorship at the time of treatment (log rank test; P = .84).
The main advantage of this study is that it is the first involving a large cohort to evaluate the effect of HCV infection on autoimmune cytopenias. However, there were several potential limitations. These included that the diagnoses of ITP and AIHA were not confirmed through a review of the medical records; that the calculation of the cumulative incidence of ITP and AIHA did not take into consideration other competing risks, which could have resulted in biased estimates; that the study involved a relatively short follow-up, which resulted in fewer ITP and AIHA events, thereby limiting the power to detect differences; that the incidence rates of ITP and AIHA in this study were higher than the incidence rates previously reported for the general population; that the HCV genotype or the rates of sustained virologic response after treatment were not confirmed via laboratory data; that there was a limited ability to account for bias introduced by other factors, which resulted in patients being excluded from treatment based on their physician's decision; and last, that the study population was made up almost entirely (96.5%) of men.
Several biological mechanisms have been suggested to explain the relationship between HCV infection and the development of ITP. The current findings illustrate that chronic HCV infection may cause ITP via a platelet-specific mechanism in addition to the occurrence of generalized autoimmunity. Thus, the researchers suggest that the term "HCV-associated thrombocytopenias" may be appropriate for future studies. Furthermore, interferon alfa has previously been associated with ITP and AIHA. The results of this study reinforce the theory that immunomodulatory effects of interferon alfa many cause an increased risk for autoimmune cytopenia.
"Future research is needed to clarify the underlying mechanisms and implications of our findings," conclude the authors.
This study was supported by the Intramural Program of the National Cancer Institute, National Institutes of Health, and the Houston VA Health Services Research and Development Center of Excellence. The authors have disclosed no relevant financial relationships.
Arch Intern Med. 2009;169:357–363.
There is a recent study that showed that many Hep C patient have ITP. Perhaps you can use it to get your doctor to prescribe it for you.
Co
HCV-Infected Individuals at Increased Risk for Immune Thrombocytopenia Purpura and Autoimmune Hemolytic Anemia.
Eurona Earl Tilley
February 26, 2009 — The incidence of 2 severe autoimmune cytopenias — immune thrombocytopenia purpura (ITP) and autoimmune hemolytic anemia (AIHA) — has been shown to be elevated among individuals infected with hepatitis C virus (HCV). Research published in the February 23 issue of the Archives of Internal Medicine reveals that HCV-infected patients in the Veterans Affairs (VA) health system were at increased risk of developing ITP. However, those who underwent treatment were also at increased risk for AIHA.
"Prior studies suggesting that HCV might be an etiologic risk factor for the development of autoimmune cytopenias have been based on small series of patients from single institutions," write Elizabeth W. Chiao, MD, MPH, from the Department of Medicine, Baylor College of Medicine, Houston, and the Houston Center for Quality of Care and Utilization Studies, Health Service Research and Development Service, Michael E. DeBakey Veterans Affairs Medical Center, Texas, and colleagues. "To our knowledge, no large study has been conducted. Given that US military veterans have a high prevalence of HCV infection (5%), this population provides a unique opportunity to observe HCV-related phenomena."
To determine the effect of HCV infection on the incidence rates of ITP and AIHA, researchers analyzed the inpatient and outpatient records as well as pharmacy data from HCV-infected (n = 120,691) and matched uninfected (n = 454,905) veterans. The diagnosis of ITP and AIHA was identified via hospitalization codes. Those with a prior diagnosis of lymphoproliferative disease, HIV, or cirrhosis were excluded from the analysis.
"In this large national cohort study including over half a million US veterans, we observed HCV-infected persons to be at increased risk of ITP and AIHA," explain the authors. A Cox proportional hazards regression model revealed that the hazard ratios (HRs) for ITP and AIHA were 1.8 (95% confidence interval [CI], 1.4 – 2.3) and 2.8 (95% CI, 1.8 – 4.2), respectively.
"Because both ITP and AIHA have been previously associated with interferon alfa use, we were also interested in assessing pharmacy data to account for the effects of HCV treatment," write Dr. Chiao and colleagues. While the incidence of ITP was elevated among both treated and untreated HCV-infected individuals, the incidence of AIHA was only elevated among those who had received treatment (HR, 11.6; 95% CI, 7.0 – 19.3).
These findings were further illustrated by examining the Kaplan-Meier curves of the cumulative incidence of each of the outcomes. The cumulative incidence of ITP was significantly greater among HCV-infected individuals vs matched control individuals (P < .001) and remained significant following censorship at the time of treatment (log rank test; P = .002). However, the cumulative incidence of AIHA was significantly greater among HCV-infected individuals vs matched control individuals (P < .001), but this difference was no longer significant following censorship at the time of treatment (log rank test; P = .84).
The main advantage of this study is that it is the first involving a large cohort to evaluate the effect of HCV infection on autoimmune cytopenias. However, there were several potential limitations. These included that the diagnoses of ITP and AIHA were not confirmed through a review of the medical records; that the calculation of the cumulative incidence of ITP and AIHA did not take into consideration other competing risks, which could have resulted in biased estimates; that the study involved a relatively short follow-up, which resulted in fewer ITP and AIHA events, thereby limiting the power to detect differences; that the incidence rates of ITP and AIHA in this study were higher than the incidence rates previously reported for the general population; that the HCV genotype or the rates of sustained virologic response after treatment were not confirmed via laboratory data; that there was a limited ability to account for bias introduced by other factors, which resulted in patients being excluded from treatment based on their physician's decision; and last, that the study population was made up almost entirely (96.5%) of men.
Several biological mechanisms have been suggested to explain the relationship between HCV infection and the development of ITP. The current findings illustrate that chronic HCV infection may cause ITP via a platelet-specific mechanism in addition to the occurrence of generalized autoimmunity. Thus, the researchers suggest that the term "HCV-associated thrombocytopenias" may be appropriate for future studies. Furthermore, interferon alfa has previously been associated with ITP and AIHA. The results of this study reinforce the theory that immunomodulatory effects of interferon alfa many cause an increased risk for autoimmune cytopenia.
"Future research is needed to clarify the underlying mechanisms and implications of our findings," conclude the authors.
This study was supported by the Intramural Program of the National Cancer Institute, National Institutes of Health, and the Houston VA Health Services Research and Development Center of Excellence. The authors have disclosed no relevant financial relationships.
Arch Intern Med. 2009;169:357–363.
Google "Promacta'. And, search recent threads here. There are two forum posters who are taking it with hcv treatment or a prelude to treatment.
It's "eltrombopag" :)
One quickly located article that I found to be nicely detailed:
http://www.pharmiweb.com/features/feature.asp?ROW_ID=933
I see this is going into Phase III trials and it's exciting that that you're able to get in on this. Timing is everything sometimes, isn't it.
Data in hepatitis C
"Phase II data for eltrompobag in hepatitis C were presented at the American Association for the Study of Liver Disease meeting on 30th October this year and were also positive. In a study of 74 patients, 95 per cent treated with the highest dose of eltrombopag had increased platelet counts and two thirds of patients in all treatment groups were able to be maintained on anti-viral treatment.
At this year’s Digestive Disease Week conference in Los Angeles, results were presented for a double-blind multicentre phase II study of eltrombopag in 33 chronic hepatitis C patients. This patient group had compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/mL. They were randomised to placebo or either 30mg, 50mg or 75mg of eltrombopag for four weeks. At the end of this time, patients achieving platelet counts above 70,000/mL were to be allowed to start pegylated interferon-alpha and ribavirin treatment.
Results showed that among patients achieving a platelet count of 100,000/mL or more, the highest response rate (90%) occurred among those receiving the 75mg dose. At lower dosages, there was still a good response rate but no patients achieved this target in the placebo group."
What trial details do you have? I found this on clinicaltrials.gov and it mentions Toronto is not yet recruiting so wonder if this is yours or something similar?
http://www.clinicaltrials.gov/ct2/show/study/NCT00516321?term=eltrombopag+hepatitis+C&rank=1&show_locs=Y#locn
Trish
One quickly located article that I found to be nicely detailed:
http://www.pharmiweb.com/features/feature.asp?ROW_ID=933
I see this is going into Phase III trials and it's exciting that that you're able to get in on this. Timing is everything sometimes, isn't it.
Data in hepatitis C
"Phase II data for eltrompobag in hepatitis C were presented at the American Association for the Study of Liver Disease meeting on 30th October this year and were also positive. In a study of 74 patients, 95 per cent treated with the highest dose of eltrombopag had increased platelet counts and two thirds of patients in all treatment groups were able to be maintained on anti-viral treatment.
At this year’s Digestive Disease Week conference in Los Angeles, results were presented for a double-blind multicentre phase II study of eltrombopag in 33 chronic hepatitis C patients. This patient group had compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/mL. They were randomised to placebo or either 30mg, 50mg or 75mg of eltrombopag for four weeks. At the end of this time, patients achieving platelet counts above 70,000/mL were to be allowed to start pegylated interferon-alpha and ribavirin treatment.
Results showed that among patients achieving a platelet count of 100,000/mL or more, the highest response rate (90%) occurred among those receiving the 75mg dose. At lower dosages, there was still a good response rate but no patients achieved this target in the placebo group."
What trial details do you have? I found this on clinicaltrials.gov and it mentions Toronto is not yet recruiting so wonder if this is yours or something similar?
http://www.clinicaltrials.gov/ct2/show/study/NCT00516321?term=eltrombopag+hepatitis+C&rank=1&show_locs=Y#locn
Trish
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
